Kyowa Kirin Co., Ltd.
Consolidated Financial Summary (IFRS)
Fiscal 2020 Second Quarter
(January 1, 2020 - June 30, 2020)
This document is an English translation of the Japanese-language original.
Kyowa Kirin Co., Ltd. (4151)
SUMMARY OF CONSOLIDATED FINANCIAL STATEMENTS (IFRS)
for Six Months Ended June 30, 2020
July 30, 2020 | |||||||||||||||
Company Name: Kyowa Kirin Co., Ltd. | Listed Exchanges: 1st Section of the Tokyo Stock Exchange | ||||||||||||||
Stock Code: | 4151 | President & Chief Executive Officer: | Masashi Miyamoto | ||||||||||||
Telephone: | +81 3 5205 7206 | Inquiries: | Satoko Yoshida | ||||||||||||
Director, | |||||||||||||||
Corporate Communications Department | |||||||||||||||
URL: | https://www.kyowakirin.com/index.html | ||||||||||||||
Scheduled date of submission of Quarterly Securities Report: July 30, 2020 | |||||||||||||||
Scheduled start date of dividend payment: September 1, 2020 | |||||||||||||||
Appendix materials to accompany the quarterly financial report: Yes | |||||||||||||||
Quarterly results presentation meeting: Yes (for institutional investors and securities analysts) | |||||||||||||||
(Millions of yen rounded off) | |||||||||||||||
1. Consolidated Financial Results for the Six Months Ended June 30, 2020 | |||||||||||||||
(1) Consolidated operating results | (Percentages indicate year-on-year changes.) | ||||||||||||||
Revenue | Core operating profit | Profit before tax | Profit | ||||||||||||
Six months ended | Millions of yen | % | Millions of yen | % | Millions of yen | % | Millions of yen | % | |||||||
June 30, 2020 | 157,819 | 4.2 | 34,479 | 7.2 | 30,872 | 41.4 | 27,798 | (42.2) | |||||||
June 30, 2019 | 151,416 | 12.7 | 48,063 | ||||||||||||
32,157 | 13.4 | 21,829 | (48.3) | 40.2 | |||||||||||
Total comprehensive income: | Six months ended June 30, 2020: ¥19,393 million; (59.4)% | ||||||||||||||
Six months ended June 30, 2019: ¥47,727 million; 58.8% |
Note: Core operating profit was calculated by deducting "selling, general and administrative expenses" and "research and development expenses" from "gross profit," and adding "share of profit (loss) of investments accounted for
using equity method" to the amount. | |||||
Profit attributable to | Basic earnings | Diluted earnings | |||
owners of parent | per share | per share | |||
Six months ended | Millions of yen | % | Yen | Yen | |
June 30, 2020 | 27,798 | (42.2) | 51.76 | 51.72 | |
June 30, 2019 | |||||
48,063 | 40.2 | 89.02 | 88.94 | ||
(2) Consolidated financial position
Ratio of equity | |||||
Total assets | Total equity | Equity attributable to | attributable to | ||
owners of parent | owners of parent to | ||||
total assets | |||||
As of | Millions of yen | Millions of yen | Millions of yen | % | |
June 30, 2020 | 779,625 | 685,906 | 685,906 | 88.0 | |
December 31, 2019 | |||||
784,453 | 678,250 | 678,250 | 86.5 | ||
1
Kyowa Kirin Co., Ltd. (4151)
2. Dividends
Dividends per share
First | Second | ||
quarter-endquarter-end | |||
Yen | Yen | ||
Fiscal year ended December 31, 2019 | - | 20.00 | |
Fiscal year ending December 31, 2020 | - | 22.00 | |
Fiscal year ending December 31, 2020 | |||
(Forecast) | |||
Note: Revisions to the dividend forecast most recently announced: None
Third | Fiscal year- | Total | |||
quarter-end | end | ||||
Yen | Yen | Yen | |||
- | 22.00 | 42.00 | |||
- | 22.00 | ||||
44.00 | |||||
3. Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2020 (from January 1, 2020 to December 31, 2020)
(Percentages indicate year-on-year changes.) | ||||||||||||||||
Profit | Basic | |||||||||||||||
Core operating | attributable to | |||||||||||||||
Revenue | Profit before tax | Profit | earnings per | |||||||||||||
profit | owners of | share | ||||||||||||||
parent | ||||||||||||||||
Millions | % | Millions | % | Millions | % | Millions | % | Millions | % | Yen | ||||||
of yen | of yen | of yen | of yen | of yen | ||||||||||||
Full year | 313,000 | 2.3 | 60,000 | 1.1 | 53,000 | 19.1 | 44,000 | (34.4) | 44,000 | (34.4) | 81.92 | |||||
Note: Changes to the earnings forecasts most recently announced: Yes |
* Notes
- Changes to significant subsidiaries during the period (Changes of specified subsidiaries resulting in changes in the scope of consolidation during the period under review): No
- Changes in accounting policies, and accounting estimates:
- Changes in accounting policies required by IFRS: No
- Changes in accounting policies other than a. above: No
- Changes in accounting estimates: No
- Number of shares issued (ordinary shares)
- Number of shares issued (including treasury shares)
As of June 30, 2020 | 540,000,000 shares |
As of December 31, 2019 | 540,000,000 shares |
b. Number of treasury shares
As of June 30, 2020 | 2,832,066 shares | |||
As of December 31, 2019 | 3,053,335 shares | |||
c. Average number of shares during the period
Six months ended June 30, 2020 | 537,054,763 shares |
Six months ended June 30, 2019 | 539,909,061 shares |
2
Kyowa Kirin Co., Ltd. (4151)
- Quarterly financial results reports are exempt from quarterly review conducted by certified public accountants or an audit corporation.
-
Notice regarding the appropriate use of the earnings forecasts and other special comments
The forward-looking statements, including earnings forecasts, contained in these materials are based on the information currently available to the Company and on certain assumptions deemed to be reasonable by management. As such, they do not constitute guarantees by the Company of future performance. Actual results may differ materially from these projections for a wide variety of reasons.
3
Kyowa Kirin Co., Ltd. (4151) | ||
Attachment Index | ||
1. Operating Results and Financial Statements...................................................................................... | 5 | |
(1) | Summary of Consolidated Business Performance ....................................................................... | 5 |
(2) | Summary of Consolidated Financial Position................................................................................ | 7 |
(3) | Summary of Consolidated Cash Flows ......................................................................................... | 8 |
(4) | Research and Development Activities........................................................................................... | 8 |
(5) | Summary of Consolidated Earnings Forecasts and Other Forward-looking Statements........... | 11 |
2. Condensed Quarterly Consolidated Financial Statements and Significant Notes Thereto .............. | 12 | |
(1) | Condensed Quarterly Consolidated Statement of Financial Position......................................... | 12 |
(2) | Condensed Quarterly Consolidated Statement of Profit or Loss and Condensed Quarterly | |
Consolidated Statement of Comprehensive Income................................................................... | 14 | |
(3) | Condensed Quarterly Consolidated Statement of Changes in Equity........................................ | 16 |
(4) | Condensed Quarterly Consolidated Statement of Cash Flows .................................................. | 18 |
(5) | Notes to Condensed Quarterly Consolidated Financial Statements .......................................... | 19 |
Notes on going concern assumption........................................................................................ | 19 | |
Segment information................................................................................................................... | 19 |
4
Kyowa Kirin Co., Ltd. (4151)
1. Operating Results and Financial Statements
(1) Summary of Consolidated Business Performance
1) Overview of results
Since applying IFRS, the Group adopts "core operating profit" as a level of profit that shows the recurring profitability from operating activities. Core operating profit is calculated by deducting "selling, general and administrative expenses" and "research and development expenses" from "gross profit," and adding "share of profit (loss) of investments accounted for using equity method" to the amount.
(Billions of yen) | ||||
Six months | Six months | Year-on-year | Year-on-year | |
ended | ended | |||
change | (%) | |||
June 30, 2020 | June 30, 2019 | |||
Revenue | 157.8 | 151.4 | 6.4 | 4.2% |
Core operating profit | 34.5 | 32.2 | 2.3 | 7.2% |
Profit before tax | 30.9 | 21.8 | 9.0 | 41.4% |
Profit from continuing operations | 27.8 | 18.7 | 9.1 | 49.0% |
Profit from discontinued operations | - | 29.4 | (29.4) | -% |
Profit attributable to owners of parent | 27.8 | 48.1 | (20.3) | (42.2)% |
For the six months ended June 30, 2020 (January 1, 2020 to June 30, 2020), revenue was ¥157.8 billion (up 4.2% compared to the same period of the previous fiscal year), and core operating profit was ¥34.5 billion (up 7.2%). Profit attributable to owners of parent was ¥27.8 billion (down 42.2%).
- The increase in revenue was the result of steady growth of global strategic products in North America and EMEA and strong sales in Asia, mainly in China, despite the impact of reduction in drug price standards and switching to Darbepoetin Alfa Injection Syringe [KKF], an authorized generic of NESP®, a renal anemia treatment drug, etc. in Japan. The increase in core operating profit was the result of an increase in gross profit due to an increase in overseas revenue, despite an increase in selling, general and administrative expenses.
- Profit attributable to owners of parent decreased as a result of the absence of the profit from discontinued operations recorded in the same period of the previous fiscal year, despite lower business restructuring expenses and impairment losses in addition to an increase in core operating profit.
- Revenue by regional control function
(Billions of yen) | |||
Six months ended | Six months ended | Year-on-year change | |
June 30, 2020 | June 30, 2019 | ||
Japan | 82.1 | 90.3 | (8.3) |
North America | 27.6 | 16.3 | 11.3 |
EMEA | 25.1 | 22.2 | 2.9 |
Asia/Oceania | 12.3 | 11.4 | 0.9 |
Others | 10.7 | 11.2 | (0.5) |
Total consolidated revenue | 157.8 | 151.4 | 6.4 |
Notes: 1. Revenue by regional control function is classified based on consolidated revenue from products of regional control functions in the One Kyowa Kirin structure (a global management structure with axes combining four regions - Japan, North America, EMEA, and Asia/Oceania - and the functions needed by a global specialty pharmaceutical company).
- EMEA consists of Europe, the Middle East, Africa, etc.
- Others consists of technology out-licensing and original equipment manufacturing, etc.
5
Kyowa Kirin Co., Ltd. (4151)
- Revenue in Japan decreased year on year because of the significant impact of switching to Darbepoetin Alfa Injection Syringe [KKF], an authorized generic of NESP®, a renal anemia treatment drug whose patent has expired, in addition to the impact of the reductions in drug price standards
implemented in October 2019 and April 2020, despite the growth in sales of new product groups.
- Darbepoetin Alfa Injection Syringe [KKF] achieved rapid progress in switching from NESP®, a renal anemia treatment drug.
- Revenue from Patanol®, anti-allergy eye drops, and ALLELOCK®, an anti-allergy agent, decreased as a result of smaller pollen counts and the impact of the suppression of examinations, etc. due to the novel coronavirus disease (COVID-19).
- Revenue from ORKEDIA®, a treatment for secondary hyperparathyroidism, increased. Meanwhile, revenue from REGPARA®, a treatment for secondary hyperparathyroidism, decreased due to factors such as switching to ORKEDIA® and the impact of rival products.
- Revenue from ROMIPLATE®, a treatment for chronic idiopathic thrombocytopenic purpura, increased as a result of receiving approval of its indication for treatment of patients with aplastic anemia who have had an inadequate response to conventional therapy, in June 2019.
- Firm growth in revenue was realized for G-Lasta®, an agent for decreasing the incidence of febrile neutropenia, and Rituximab BS [KHK], an anticancer agent.
- In December 2019, Crysvita®, a treatment for FGF23-related diseases, and HARUROPI®, a
Parkinson's disease treatment patch, were launched and they have been penetrating the market favorably.
- Revenue in North America increased year on year due to the steady growth of global strategic
products.
- Sales of Crysvita®, a treatment for X-linked hypophosphatemia, have been growing steadily since its launch in 2018.
- Revenue from POTELIGEO®, an anticancer agent, stayed at the same level as in the same period of the previous fiscal year due to the impact of the COVID-19 pandemic.
- NOURIANZ™ (product name in Japan: NOURIAST®), an antiparkinsonian agent which was
launched in October 2019, has been penetrating the market favorably.
- Revenue in EMEA increased year on year due to the steady growth of global strategic products.
- Sales of Crysvita®, a treatment for X-linked hypophosphatemia, have been growing steadily as the number of countries where it has been released has been increasing since its launch in 2018.
- In Germany, POTELIGEO®, an anticancer agent, was launched in June.
- Revenue in Asia/Oceania increased year on year, reflecting strong sales particularly in China.
- Revenue from REGPARA®, a treatment for secondary hyperparathyroidism, increased compared to the same period of the previous fiscal year due to market expansion in China.
- Revenue from Others decreased year on year.
- Revenue decreased from the same period of the previous fiscal year due mainly to a decline in milestone revenue despite an increase in royalties revenue from AstraZeneca in relation to benralizumab.
6
Kyowa Kirin Co., Ltd. (4151)
3) Core operating profit
Billions of yen
40.0 | +4.1 | -2.9 | |||||||
+0.8 | +0.4 | +2.3 | |||||||
30.0 | |||||||||
20.0 | |||||||||
32.2 | 34.5 | ||||||||
10.0 | |||||||||
0.0 | |||||||||
Jan. - Jun. 2019 | Gross profit | Selling, general and | Research and development | Share of profit (loss) of | Jan. - Jun. 2020 | ||||
administrative expenses | expenses | investments accounted for | |||||||
using equity method |
- Core operating profit increased compared to the same period of the previous fiscal year due to an increase in overseas revenue mainly from global strategic products, despite a decrease in revenue in Japan and an increase in selling, general and administrative expenses associated with sales of global strategic products.
- Summary of Consolidated Financial Position
(Billions of yen) | |||
As of | As of | Change | |
June 30, 2020 | December 31, 2019 | ||
Assets | 779.6 | 784.5 | (4.8) |
Non-current assets | 346.4 | 335.8 | 10.6 |
Current assets | 433.2 | 448.6 | (15.4) |
Liabilities | 93.7 | 106.2 | (12.5) |
Equity | 685.9 | 678.2 | 7.7 |
Ratio of equity attributable to owners of | 88.0% | 86.5% | 1.5% |
parent to total assets (%) | |||
- Assets as of June 30, 2020, were ¥779.6 billion, a decrease of ¥4.8 billion compared to the end of the previous fiscal year.
- Non-currentassets increased by ¥10.6 billion to ¥346.4 billion, due mainly to an increase in deferred tax assets as well as an increase in intangible assets associated with in-licensing of development products.
- Current assets decreased by ¥15.4 billion to ¥433.2 billion, due mainly to a decrease in cash reserves (cash and cash equivalents and loans receivable from parent) due to income taxes and dividends paid, and purchase of intangible assets, despite large increases in cash and cash equivalents due to the impact of an increase of ¥204.0 billion within loans receivable from parent
with loan periods of three months or less included in the scope of cash and cash equivalents.
- Liabilities as of June 30, 2020, were ¥93.7 billion, a decrease of ¥12.5 billion compared to the end of the previous fiscal year, due mainly to decreases in trade and other payables and income taxes payable.
7
Kyowa Kirin Co., Ltd. (4151)
- Equity as of June 30, 2020, was ¥685.9 billion, an increase of ¥7.7 billion compared to the end of the previous fiscal year, due mainly to an increase due to the recording of profit attributable to owners of parent, despite a decrease due to the payment of dividends as well as a decrease in exchange differences on translation of foreign operations resulting from the impact of exchange rates, etc. As a result, the ratio of equity attributable to owners of parent to total assets as of the end of the second quarter was 88.0%, an increase of 1.5 percentage points compared to the end of the previous fiscal year.
- Summary of Consolidated Cash Flows
(Billions of yen)
Six months ended Six months ended Year-on-year | Year-on-year | |||
June 30, 2020 | June 30, 2019 | change | (%) | |
Net cash provided by (used in) operating activities | 20.6 | 19.8 | 0.8 | 3.8% |
Net cash provided by (used in) investing activities | 216.5 | 10.6 | 205.9 | 1,934.1% |
Net cash provided by (used in) financing activities | (13.3) | (35.2) | 21.9 | (62.2)% |
Cash and cash equivalents at beginning of period | 20.8 | 15.9 | 4.9 | 30.9% |
Cash and cash equivalents at end of period | 243.5 | 10.9 | 232.6 | 2,130.2% |
- Cash and cash equivalents as of June 30, 2020, were ¥243.5 billion, an increase of ¥222.8 billion compared with the balance of ¥20.8 billion as of December 31, 2019 as a result of the impact of an increase of ¥204.0 billion within loans receivable from parent with loan periods of three months or less included in the scope of cash and cash equivalents.
The main contributing factors affecting cash flow during the six months ended June 30, 2020 were as follows: - Net cash provided by operating activities was ¥20.6 billion, a 3.8% increase compared to the same period of the previous fiscal year. Major inflows included profit before tax of ¥30.9 billion and depreciation and amortization of ¥9.2 billion. Major outflows included income taxes paid of ¥16.2 billion.
- Net cash provided by investing activities was ¥216.5 billion, a 1,934.1% increase compared to the same period of the previous fiscal year. Major inflows included a net decrease of ¥233.8 billion in loans receivable from parent. Major outflows included ¥11.5 billion for purchase of intangible assets, and ¥6.1 billion for purchase of property, plant and equipment.
- Net cash used in financing activities was ¥13.3 billion, a 62.2% decrease compared to the same period of the previous fiscal year. Major outflows included dividends paid of ¥11.8 billion.
- Research and Development Activities
Using cutting-edge biotechnology centered on antibody technology, we have made nephrology, oncology, immunology/allergy and central nervous system (CNS) the focus of research and development, and by investing resources efficiently, we aim to further speed up the creation of new medical value and drug creation.
For the six months ended June 30, 2020, the Group's research and development expenses totaled ¥24.1 billion, and the progress of our main late-stage development products are as follows. ("◆" indicates the progress made during the second quarter of fiscal 2020.)
Nephrology
KRN321 (product name in Japan: NESP®)
- In June, we obtained approval of its indication for treatment of renal anemia in patients receiving hemodialysis in China.
8
Kyowa Kirin Co., Ltd. (4151)
Oncology
KRN125 (product name in Japan: G-Lasta®)
- In February, we started a phase I clinical study in Japan related to the development of an automated injection device for decreasing the incidence of febrile neutropenia in patients receiving cancer chemotherapy.
ME-401
- In the U.S., Europe, South Korea, Australia, etc., we are currently conducting a phase II clinical trial for treatment of follicular lymphoma. (In April, we concluded an agreement with MEI Pharma on global license, development, and commercialization.)
Immunology and allergy
KHK4827 (product name in Japan: LUMICEF®)
- In June, we obtained approval of its indication for treatment of plaque psoriasis in China.
Central nervous system (CNS)
KW-6002 (product name in Japan: NOURIAST®; product name in U.S.: NOURIANZ™)
- In January, an application for approval of its indication for combination therapy with levodopa-based regimens for adult patients with Parkinson's disease experiencing "off" episodes was accepted in Europe (application filed in November 2019).
Other
KRN23 (product name in Japan, U.S. and Europe: Crysvita®)
- In February in the U.S., we obtained approval for partial changes to our biologics license application for approval of its indication for treatment of tumor induced osteomalacia that cannot be curatively resected or localized, and in June, we obtained approval of its indication for treatment of tumor induced osteomalacia that cannot be curatively resected or localized for adult patients and pediatric patients who are two years of age or older.
9
Kyowa Kirin Co., Ltd. (4151)
10
Kyowa Kirin Co., Ltd. (4151)
(5) Summary of Consolidated Earnings Forecasts and Other Forward-looking Statements
Revenue for the six months ended June 30, 2020 was lower than initial expectations due to the impact on Darbepoetin Alfa Injection Syringe [KKF], an authorized generic of NESP®, a renal anemia treatment drug, as biosimilar products penetrated the market in Japan. In addition, in the second half of the fiscal year there are concerns that the market penetration speed of global strategic products, such as Crysvita® and POTELIGEO® with sales that have been growing steadily as the number of countries where they have been released has been increasing since their launch in 2018 and 2019 in North America and EMEA, will be slower than initial expectations due to the prolonged outbreak of COVID-19. Furthermore, other expenses increased due to the recording of impairment losses, business restructuring expenses, etc.
In light of these trends in business results, etc., we have revised the full-year consolidated earnings forecasts.
The differences from the full-year consolidated earnings forecasts for the fiscal year ending December 31, 2020 announced February 5, 2020 are as follows.
(Full year)
Revenue | Core operating | Profit before tax | Profit attributable | Basic earnings | |
profit | to owners of parent | per share | |||
(Millions of yen) | (Millions of yen) | (Millions of yen) | (Millions of yen) | (Yen) | |
Previous forecast (A) | 327,000 | 65,000 | 63,000 | 49,000 | 91.26 |
Revised forecast (B) | 313,000 | 60,000 | 53,000 | 44,000 | 81.92 |
Change (B-A) | (14,000) | (5,000) | (10,000) | (5,000) | - |
Rate of change (%) | (4.3)% | (7.7)% | (15.9)% | (10.3)% | - |
Fiscal 2019 results | 305,820 | 59,353 | 44,492 | 67,084 | 124.57 |
11
Kyowa Kirin Co., Ltd. (4151)
2. Condensed Quarterly Consolidated Financial Statements and Significant Notes Thereto
(1) Condensed Quarterly Consolidated Statement of Financial Position
(Millions of yen) | |||
As of | As of | ||
June 30, 2020 | December 31, 2019 | ||
Assets | |||
Non-current assets | |||
Property, plant and equipment | 74,698 | 74,216 | |
Goodwill | 130,937 | 133,554 | |
Intangible assets | 66,409 | 60,106 | |
Investments accounted for using equity method | 13,764 | 13,526 | |
Other financial assets | 18,794 | 19,511 | |
Retirement benefit asset | 12,045 | 12,299 | |
Deferred tax assets | 29,299 | 22,110 | |
Other non-current assets | 468 | 520 | |
Total non-current assets | 346,414 | 335,843 | |
Current assets | |||
Inventories | 46,742 | 47,123 | |
Trade and other receivables | 85,239 | 89,015 | |
Loans receivable from parent | 51,900 | 285,700 | |
Other financial assets | 571 | 389 | |
Other current assets | 5,238 | 5,621 | |
Cash and cash equivalents | 243,521 | 20,762 | |
Total current assets | 433,211 | 448,610 | |
Total assets | 779,625 | 784,453 | |
12
Kyowa Kirin Co., Ltd. (4151)
(1) Condensed Quarterly Consolidated Statement of Financial Position (continued)
(Millions of yen) | ||
As of | As of | |
June 30, 2020 | December 31, 2019 | |
Equity | ||
Share capital | 26,745 | 26,745 |
Capital surplus | 463,925 | 463,893 |
Treasury shares | (3,611) | (3,792) |
Retained earnings | 217,165 | 201,253 |
Other components of equity | (18,319) | (9,849) |
Total equity attributable to owners of parent | 685,906 | 678,250 |
Total equity | 685,906 | 678,250 |
Liabilities | ||
Non-current liabilities | ||
Retirement benefit liability | 399 | 276 |
Provisions | 1,646 | 1,648 |
Deferred tax liabilities | 46 | 42 |
Other financial liabilities | 15,235 | 15,444 |
Other non-current liabilities | 1,126 | 1,263 |
Total non-current liabilities | 18,452 | 18,673 |
Current liabilities | ||
Trade and other payables | 45,153 | 53,877 |
Provisions | 2,856 | 2,019 |
Other financial liabilities | 2,978 | 3,109 |
Income taxes payable | 10,423 | 15,214 |
Other current liabilities | 13,858 | 13,312 |
Total current liabilities | 75,267 | 87,530 |
Total liabilities | 93,720 | 106,204 |
Total equity and liabilities | 779,625 | 784,453 |
13
Kyowa Kirin Co., Ltd. (4151)
-
Condensed Quarterly Consolidated Statement of Profit or Loss and Condensed Quarterly Consolidated Statement of Comprehensive Income
Condensed Quarterly Consolidated Statement of Profit or Loss
(Millions of yen) | |||
January 1, 2020 to | January 1, 2019 to | ||
June 30, 2020 | June 30, 2019 | ||
Continuing operations | |||
Revenue | 157,819 | 151,416 | |
Cost of sales | (40,951) | (38,617) | |
Gross profit | 116,868 | 112,799 | |
Selling, general and administrative expenses | (58,234) | (55,307) | |
Research and development expenses | (24,070) | (24,879) | |
Share of profit (loss) of investments accounted for using | (86) | (456) | |
equity method | |||
Other income | 657 | 181 | |
Other expenses | (5,299) | (10,463) | |
Finance income | 1,149 | 483 | |
Finance costs | (114) | (530) | |
Profit before tax | 30,872 | 21,829 | |
Income tax expense | (3,074) | (3,176) | |
Profit from continuing operations | 27,798 | 18,653 | |
Discontinued operations | |||
Profit from discontinued operations | - | 29,410 | |
Profit | 27,798 | 48,063 | |
Profit attributable to | |||
Owners of parent | 27,798 | 48,063 | |
Earnings per share | |||
Basic earnings per share (Yen) | 51.76 | 89.02 | |
Continuing operations | 51.76 | 34.55 | |
Discontinued operations | - | 54.47 | |
Diluted earnings per share (Yen) | 51.72 | 88.94 | |
Continuing operations | 51.72 | 34.52 | |
Discontinued operations | - | 54.42 |
14
Kyowa Kirin Co., Ltd. (4151)
Condensed Quarterly Consolidated Statement of Comprehensive Income
(Millions of yen) | ||
January 1, 2020 to | January 1, 2019 to | |
June 30, 2020 | June 30, 2019 | |
Profit | 27,798 | 48,063 |
Other comprehensive income | ||
Items that will not be reclassified to profit or loss | ||
Financial assets measured at fair value through other | (534) | 474 |
comprehensive income | ||
Share of other comprehensive income of investments | (72) | (41) |
accounted for using equity method | ||
Total of items that will not be reclassified to profit or loss | (606) | 433 |
Items that may be reclassified to profit or loss
Exchange differences on translation of foreign operations
Share of other comprehensive income of investments accounted for using equity method
Total of items that may be reclassified to profit or loss Other comprehensive income
Comprehensive income
(7,759)(709)
(40)(61)
(7,799)(770)
(8,406)(337)
19,39347,727
Comprehensive income attributable to | ||
Owners of parent | 19,393 | 47,727 |
15
Kyowa Kirin Co., Ltd. (4151)
- Condensed Quarterly Consolidated Statement of Changes in Equity January 1, 2020 to June 30, 2020
(Millions of yen) | ||||||||
Equity attributable to owners of parent | ||||||||
Other components of equity | ||||||||
Retained | Exchange | |||||||
Share capital | Capital surplus | Treasury shares | Share | differences on | ||||
earnings | ||||||||
translation of | ||||||||
acquisition rights | ||||||||
foreign | ||||||||
operations | ||||||||
Balance at January 1, 2020 | 26,745 | 463,893 | (3,792) | 201,253 | 751 | (13,647) | ||
Profit | - | - | - | 27,798 | - | - | ||
Other comprehensive income | - | - | - | - | - | (7,799) | ||
Total comprehensive income | - | - | - | 27,798 | - | (7,799) | ||
Dividends of surplus | - | - | - | (11,813) | - | - | ||
Purchase of treasury shares | - | - | (7) | - | - | - | ||
Disposal of treasury shares | - | 14 | 157 | - | - | - | ||
Share-based remuneration | - | 18 | 30 | - | (137) | - | ||
transactions | ||||||||
Transfer from other | ||||||||
components of equity to | - | - | - | (73) | - | - | ||
retained earnings | ||||||||
Total transactions with owners | - | 32 | 181 | (11,885) | (137) | - | ||
Balance at June 30, 2020 | 26,745 | 463,925 | (3,611) | 217,165 | 614 | (21,446) | ||
Equity attributable to owners of parent | ||||||||
Other components of equity | ||||||||
Financial assets | ||||||||
measured at fair | Remeasure- | Total | Total equity | |||||
value through | ||||||||
ments of defined | Total | |||||||
other | benefit plans | |||||||
comprehensive | ||||||||
income | ||||||||
Balance at January 1, 2020 | 3,047 | - | (9,849) | 678,250 | 678,250 | |||
Profit | - | - | - | 27,798 | 27,798 | |||
Other comprehensive income | (534) | (73) | (8,406) | (8,406) | (8,406) | |||
Total comprehensive income | (534) | (73) | (8,406) | 19,393 | 19,393 | |||
Dividends of surplus | - | - | - | (11,813) | (11,813) | |||
Purchase of treasury shares | - | - | - | (7) | (7) | |||
Disposal of treasury shares | - | - | - | 171 | 171 | |||
Share-based remuneration | - | - | (137) | (89) | (89) | |||
transactions | ||||||||
Transfer from other | ||||||||
components of equity to | - | 73 | 73 | - | - | |||
retained earnings | ||||||||
Total transactions with owners | - | 73 | (64) | (11,737) | (11,737) | |||
Balance at June 30, 2020 | 2,513 | - | (18,319) | 685,906 | 685,906 | |||
16
Kyowa Kirin Co., Ltd. (4151)
- Condensed Quarterly Consolidated Statement of Changes in Equity (continued) January 1, 2019 to June 30, 2019
(Millions of yen) | |||||||||
Equity attributable to owners of parent | |||||||||
Other components of equity | |||||||||
Retained | Exchange | ||||||||
Share capital | Capital surplus | Treasury shares | Share | differences on | |||||
earnings | |||||||||
translation of | |||||||||
acquisition rights | |||||||||
foreign | |||||||||
operations | |||||||||
Balance at January 1, 2019 | 26,745 | 509,161 | (26,705) | 151,760 | 787 | (16,402) | |||
Changes in accounting policies | - | - | - | (454) | - | - | |||
Balance after restatement | 26,745 | 509,161 | (26,705) | 151,306 | 787 | (16,402) | |||
Profit | - | - | - | 48,063 | - | - | |||
Other comprehensive income | - | - | - | - | - | (770) | |||
Total comprehensive income | - | - | - | 48,063 | - | (770) | |||
Dividends of surplus | - | - | - | (10,949) | - | - | |||
Purchase of treasury shares | - | - | (22,595) | - | - | - | |||
Disposal of treasury shares | - | (17) | 263 | - | - | - | |||
Cancellation of treasury shares | - | (45,251) | 45,251 | - | - | - | |||
Share-based remuneration | - | - | - | - | (137) | - | |||
transactions | |||||||||
Transfer from other | |||||||||
components of equity to | - | - | - | 134 | - | - | |||
retained earnings | |||||||||
Total transactions with owners | - | (45,269) | 22,919 | (10,814) | (137) | - | |||
Balance at June 30, 2019 | 26,745 | 463,893 | (3,786) | 188,555 | 650 | (17,171) | |||
Equity attributable to owners of parent | |||||||||
Other components of equity | |||||||||
Financial assets | |||||||||
measured at fair | Remeasure- | Total | Total equity | ||||||
value through | |||||||||
ments of defined | Total | ||||||||
other | benefit plans | ||||||||
comprehensive | |||||||||
income | |||||||||
Balance at January 1, 2019 | 4,275 | - | (11,341) | 649,621 | 649,621 | ||||
Changes in accounting policies | - | - | - | (454) | (454) | ||||
Balance after restatement | 4,275 | - | (11,341) | 649,166 | 649,166 | ||||
Profit | - | - | - | 48,063 | 48,063 | ||||
Other comprehensive income | 475 | (42) | (337) | (337) | (337) | ||||
Total comprehensive income | 475 | (42) | (337) | 47,727 | 47,727 | ||||
Dividends of surplus | - | - | - | (10,949) | (10,949) | ||||
Purchase of treasury shares | - | - | - | (22,595) | (22,595) | ||||
Disposal of treasury shares | - | - | - | 246 | 246 | ||||
Cancellation of treasury shares | - | - | - | - | - | ||||
Share-based remuneration | - | - | (137) | (137) | (137) | ||||
transactions | |||||||||
Transfer from other | |||||||||
components of equity to | (176) | 42 | (134) | - | - | ||||
retained earnings | |||||||||
Total transactions with owners | (176) | 42 | (271) | (33,435) | (33,435) | ||||
Balance at June 30, 2019 | 4,573 | - | (11,949) | 663,458 | 663,458 | ||||
17
Kyowa Kirin Co., Ltd. (4151) | ||||
(4) Condensed Quarterly Consolidated Statement of Cash Flows | ||||
(Millions of yen) | ||||
January 1, 2020 to | January 1, 2019 to | |||
June 30, 2020 | June 30, 2019 | |||
Cash flows from operating activities | ||||
Profit before tax from continuing operations | 30,872 | 21,829 | ||
Depreciation and amortization | 9,243 | 10,007 | ||
Impairment losses | 2,679 | 4,757 | ||
Share of loss (profit) of investments accounted for using | 86 | 456 | ||
equity method | ||||
Decrease (increase) in inventories | (1,090) | (4,260) | ||
Decrease (increase) in trade receivables | 1,467 | (6,693) | ||
Increase (decrease) in trade payables | (3,000) | 1,238 | ||
Income taxes paid | (16,173) | (14,574) | ||
Other | (3,528) | 736 | ||
Net cash provided by (used in) operating activities from | - | 6,297 | ||
discontinued operations | ||||
Net cash provided by (used in) operating activities | 20,555 | 19,795 | ||
Cash flows from investing activities | ||||
Purchase of property, plant and equipment | (6,114) | (4,360) | ||
Purchase of intangible assets | (11,518) | (3,693) | ||
Purchase of investments accounted for using equity | (500) | (1,000) | ||
method | ||||
Collection of loans receivable | - | 19,976 | ||
Net decrease (increase) in loans receivable from parent | 233,800 | (102,400) | ||
Other | 856 | (1,079) | ||
Net cash provided by (used in) investing activities from | - | 103,200 | ||
discontinued operations | ||||
Net cash provided by (used in) investing activities | 216,524 | 10,645 | ||
Cash flows from financing activities | ||||
Repayments of lease liabilities | (1,593) | (1,613) | ||
Purchase of treasury shares | (7) | (22,595) | ||
Dividends paid | (11,813) | (10,949) | ||
Other | 97 | (7) | ||
Net cash provided by (used in) financing activities from | - | (19) | ||
discontinued operations | ||||
Net cash provided by (used in) financing activities | (13,315) | (35,183) | ||
Effect of exchange rate changes on cash and cash | ||||
(1,006) | (204) | |||
equivalents | ||||
Net increase (decrease) in cash and cash equivalents | 222,758 | (4,947) | ||
Cash and cash equivalents at beginning of period | 20,762 | 15,867 | ||
Cash and cash equivalents at end of period | 243,521 | 10,919 | ||
18
Kyowa Kirin Co., Ltd. (4151)
- Notes to Condensed Quarterly Consolidated Financial Statements Notes on going concern assumption
No applicable items.
Segment information
As the Bio-Chemicals business was categorized as a discontinued operation effective from the previous fiscal year, the Group omitted information by reportable segment as the Group consists of only the one reportable segment, which is the Pharmaceuticals business.
19
Attachments
- Original document
- Permalink
Disclaimer
Kyowa Hakko Kirin Co. Ltd. published this content on 30 July 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 July 2020 06:35:08 UTC